



Preventive Care Guide

Effective January 1, 2025

AMB24-NE-C-00029

Preventive Care Guide

Overview (Federal Preventive Care Requirements): The federal Patient Protection and Affordable Care Act (PPACA) requires non-grandfathered health plans to cover certain services under preventive care, without cost sharing to members when provided by an in-network provider. This coverage includes:

- Evidence-based items or services that have in effect a rating of "A" or "B" in the current recommendations of the United States Preventive Services Task Force (USPSTF).
 - Published USPSTF A/B recommendations can be found at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
- Immunizations for routine use in children, adolescents and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).
 - Published ACIP recommended immunization schedules can be found at: https://www.cdc.gov/vaccines/hcp/imz-schedules/index.html
- With respect to infants, children and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA). HRSA endorses preventive guidelines established by the American Academy of Pediatrics (AAP) for the health and well-being of infants, children and adolescents. These recommendations are referred to as Bright Futures.
 - Published Bright Futures recommendations can be found at: https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf
- With respect to women, such additional preventive care and screenings as provided for in comprehensive guidelines supported by the HRSA.
 - Published HRSA recommendations (for women) can be found at: https://www.hrsa.gov/womens-guidelines

Note: Coverage of preventive care services must become effective upon a plan's start or anniversary date that is one year after the date a new recommendation or guideline is issued.

PPACA states reasonable medical management techniques may be used to determine coverage limitations if a recommendation or guideline does not specify the frequency, method, treatment, or setting for the provision of a recommended preventive service. Reasonable medical management techniques may include precertification, concurrent review, claim review, or similar practices to determine coverage limitations under the plan. These established reasonable medical management techniques and practices may be utilized to determine frequency, method, treatment or setting for the provision of a recommended preventive service.

In addition to the designated services identified by the above-listed sources, tobacco cessation treatment, wellness examinations for all populations – children and adults – and services that are integral to the furnishing of a specific preventive care benefit (e.g., anesthesia provided during sterilization surgery for women) are included under preventive care coverage.

Ambetter Health Preventive Care Coverage: All Ambetter Health plans provide preventive care coverage in accordance with the above-listed PPACA requirements. If two recommendations address the same benefit, but differ (e.g., USPSTF's breast cancer screening recommendation vs. HRSA's breast cancer screening recommendation), the richest coverage applies. Although this documentation only focuses on federal requirements (national preventive care coverage), we do cover additional preventive care benefits when required by state law.

Preventive care refers to measures or services taken to promote health and early detection/prevention of diseases and injuries, rather than treating them or curing them. Preventive care may include, but is not limited to, examinations and screening tests tailored to an individual's age, health, and family history. All preventive care received from an in-network Ambetter Health provider is covered with no cost share (i.e., covered at 100% (of the contracted amount) – without deductible, coinsurance or copayment). This coverage also includes preventive prescription medications such as contraceptives, aspirin, vitamin D and folic acid for all persons planning to or who could become pregnant. The Formulary (Prescription Drug List) can provide additional details on specific medications covered without cost share.

Please keep in mind, certain covered services can be provided for preventive or diagnostic reasons. When a covered preventive service is performed for the purpose of preventive screening and is appropriately reported (billed by the provider), it will fall under the preventive care services benefit. This includes services directly related to the performance of a covered preventive care service. Examples of preventive services are those performed on a person who:

- Has not had the preventive screening done before and does not have symptoms or other abnormal studies suggesting abnormalities; or
- Has had the preventive screening done within the recommended interval with the findings considered normal; or
- Has had diagnostic services results that were normal after which the physician recommendation would be for future preventive screening studies using the preventive services intervals.

However, when a covered service is performed for diagnostic purposes, it will not fall under preventive care, but rather under the applicable non-preventive medical benefit, which may be subject to cost share (deductible, coinsurance or copayment) depending on your plan. Examples of diagnostic services are those performed on a person who:

- Had abnormalities found on previous preventive or diagnostic studies that require further diagnostic studies; or
- Had abnormalities found on previous preventive or diagnostic studies that would recommend a repeat of the same studies within shortened time intervals from the recommended preventive screening time intervals; or
- Had a symptom(s) that required further diagnosis; or
- Does not fall within the applicable population for a recommendation or guideline.

The following table (beginning on page 3) provides an overview of available preventive care coverage. IMPORTANT: If a preventive care service is recommended for a specific gender (e.g., men or women), this is in reference to the individual's sex assigned at birth, rather than gender identity.

Acronyms:

- •AAP: American Academy of Pediatrics
- ACIP: Advisory Committee on Immunization Practices
- •CDC: Centers for Disease Control & Prevention
- •EOC: Evidence of Coverage
- •HRSA: Health Resources & Services Administration
- •MMEP: Major Medical Expense Policy
- •PPACA: Patient Protection & Affordable Care Act
- •USPSTF: United States Preventive Services Task Force
- •WPSI: Women's Preventive Services Initiative

Member Questions: For any questions regarding preventive care coverage, please talk to your physician directly or call us at the toll-free number listed on the back of your Ambetter Health ID card.

PREVENTIVE CARE SERVICES			
(New	(Newborns, Children, Adolescents and Adults)		
Service	Population	Summary	
Wellness Examinations	Children and Adults	Preventive medicine comprehensive evaluation and management services (i.e., wellness examinations) for well-baby, well-child and well-adult/woman include: • An age-and gender-appropriate history, • Physical examination, • Counseling/anticipatory guidance, • Risk factor reduction interventions, and • The ordering of appropriate immunization(s) and laboratory/screening procedures. Note: The below-listed services may be provided as part of a	
	LICOSTE'S A /D	wellness examination or at a separate encounter.	
Abdominal Aortic Aneurysm	Men USPSTF'S A/B	Recommendations USPSTF Rating (Dec. 2019): B	
Screening	Weii	The USPSTF recommends 1-time screening for abdominal aortic aneurysm with ultrasonography in men aged 65-75 years who have ever smoked.	
Anxiety Screening in Children and Adolescents	Children and Adolescents	USPSTF Rating (Oct. 2022): B The USPSTF recommends screening for anxiety in children and adolescents aged 8 to 18 years.	
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality	Pregnant Women	USPSTF Rating (Sept. 2021): B The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons who are at high risk for preeclampsia.	
Bacteriuria Screening	Pregnant Women	USPSTF Rating (Sept. 2019): B The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons.	
Behavioral Counseling to Prevent Sexually Transmitted Infections	Adolescents and Adults	USPSTF Rating (Aug. 2020): B The USPSTF recommends behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).	
Behavioral Counseling to Prevent Skin Cancer	Children, Adolescents, Young Adults and Parents of Young Children	USPSTF Rating (March 2018): B The USPSTF recommends counseling young adults, adolescents, children and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons ages 6 months to 24 years with fair skin types to reduce their risk of skin cancer.	
Breast Cancer Screening	Women	USPSTF Rating (April 2024): B The USPSTF recommends biennial screening mammography for women aged 40 to 74 years.	

PREVENTIVE CARE SERVICES			
(Newborns, Children, Adolescents and Adults)			
Service	Population	Summary	
	-	Note: Please also refer to the HRSA breast cancer screening	
		recommendation on page 10; it addresses richer coverage	
		(as frequently as annually).	
Cervical Cancer Screening	Women	USPSTF Rating (Aug. 2018): A	
		The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21-29	
		years.	
		For women 20 to 65 years of ago, the USDSTF recommender	
		For women 30 to 65 years of age, the USPSTF recommends: • Screening every 3 years with cervical cytology (pap	
		test) alone,	
		Every 5 years with high-risk human papillomavirus	
		(hrHPV) testing alone, or	
		Every 5 years with hrHPV testing in combination	
Chlamydia Infaction	Women	with cytology (cotesting).	
Chlamydia Infection Screening	women	USPSTF Rating (Sept. 2021): B The USPSTF recommends screening for chlamydia in all	
Sercering		sexually active women 24 years or younger and in women 25	
		years or older who are at increased risk for infection. This	
		recommendation applies to asymptomatic, sexually active	
		adolescents and adults, including pregnant persons.	
Cholesterol Screening (Lipid	Adults	USPSTF Rating (Aug. 2022): B	
Disorders Screening) / Statin Use for the Primary		The USPSTF recommends that adults without a history of cardiovascular disease (CVD) use a low to moderate dose	
Prevention of Cardiovascular		statin for the prevention of CVD events and mortality when	
Disease in Adults		all the following criteria are met:	
		They are aged 40 to 75 years;	
		They have 1 or more CVD risk factors (such as,	
		dyslipidemia, diabetes, hypertension or smoking); and	
		They have a calculated 10-year risk of a	
		cardiovascular event of 10% or greater.	
		Note: Identification of dyslipidemia and calculation of 10-	
		year CVD event risk requires universal lipids screening in	
		adults aged 40 to 75 years.	
Colorectal Cancer Screening	Adults	USPSTF Rating (May 2021): B	
		The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years.	
		dudits aged 45 to 45 years.	
		USPSTF Rating (May 2021): A	
		The USPSTF recommends screening for colorectal cancer in	
		all adults aged 50 to 75 years.	

PREVENTIVE CARE SERVICES		
(New	borns, Children,	Adolescents and Adults)
Service	Population	Summary
		Several recommended screening tests are available. Clinicians and patients may consider a variety of factors in deciding which testing approach is best for each person.
		Recommended intervals* for colorectal cancer screening tests include: • High-sensitivity guaiac fecal occult blood test (HSgFOBT) or fecal immunochemical test (FIT) every year, • Stool DNA-FIT every 1 to 3 years, • Computed tomography colonography every 5 years, • Flexible sigmoidoscopy every 5 years, • Flexible sigmoidoscopy every 10 years + annual FIT,
		andColonoscopy screening every 10 years.
		*IMPORTANT: If a follow-up colonoscopy is required due to a positive non-invasive stool-based screening test or direct visualization screening test for colorectal cancer, the follow-up colonoscopy screening is also considered preventive care (covered without cost share when provided by an innetwork provider). Per the USPSTF, "the follow-up colonoscopy is an integral part of the preventive screening without which the screening would not be complete."
Fluoride Application in Primary Care (Prevention of Dental Caries in Children Younger than 5 Years)	Infants and Children	USPSTF Rating (Dec. 2021): B The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.
		USPSTF Rating (Dec. 2021): B The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.
Folic Acid for the Prevention of Neural Tube Defects	Women	USPSTF Rating (Aug. 2023): A The USPSTF recommends that all persons planning to or who could become pregnant take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid.
Genetic Counseling and Evaluation for BRCA Testing and BRCA Lab Screening	Women	USPSTF Rating (Aug. 2019): B The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool.

PREVENTIVE CARE SERVICES			
(Newborns, Children, Adolescents and Adults)			
Service	Population	Summary	
		Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.	
Gestational Diabetes Screening	Pregnant Women	USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for gestational diabetes mellitus in asymptomatic pregnant persons at 24 weeks of gestation or after.	
Gonorrhea Screening	Women	USPSTF Rating (Sept. 2021): B The USPSTF recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. This recommendation applies to asymptomatic, sexually active adolescents and adults, including pregnant persons.	
Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults with Cardiovascular Risk Factors: Behavioral Counseling Interventions	Adults	USPSTF Rating (Nov. 2020): B The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.	
Healthy Weight and Weight Gain During Pregnancy: Behavioral Counseling Interventions	Pregnant Women	USPSTF Rating (May 2021): B The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.	
Hepatitis B Virus Infection Screening	Adolescents and Adults	USPSTF Rating (July 2019): A The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit. USPSTF Rating (Dec. 2020): B The USPSTF recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at high risk for infection.	
Hepatitis C Virus Infection Screening	Adults	USPSTF Rating (March 2020): B The USPSTF recommends screening for hepatitis C virus infection in adults aged 18-79 years.	
Human Immunodeficiency Virus (HIV) Screening	Adolescents and Adults	USPSTF Rating (June 2019): A The USPSTF recommends that clinicians screen for HIV infection in: • Adolescents and adults aged 15-65 years. • Younger adolescents and older adults who are at increased risk of infection should also be screened. • All pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.	
Hypertensive Disorders of Pregnancy Screening	Pregnant Persons	USPSTF Rating (Sept. 2023): B	

PREVENTIVE CARE SERVICES			
(Newborns, Children, Adolescents and Adults)			
Service	Population	Summary	
		The USPSTF recommends screening for hypertensive	
		disorders in pregnant persons with blood pressure	
		measurements throughout pregnancy.	
Interventions for High BMI in Children and Adolescents	Children and Adolescents	USPSTF Rating (June 2024): B	
Children and Adolescents	Adolescents	The USPSTF recommends that clinicians provide or refer children and adolescents 6 years or older with a high BMI	
		(greater than or equal to the 95th percentile for age and sex)	
		to comprehensive, intensive behavioral interventions.	
Interventions for Tobacco	Adults	USPSTF Rating (Jan. 2021): A	
Smoking Cessation in Adults,		The USPSTF recommends that clinicians ask all pregnant	
including Pregnant Persons		persons about tobacco use, advise them to stop using	
		tobacco, and provide behavioral interventions for cessation	
		to pregnant persons who use tobacco.	
		USPSTF Rating (Jan. 2021): A	
		The USPSTF recommends that clinicians ask all adults about	
		tobacco use, advise them to stop using tobacco, and provide	
		behavioral interventions and US Food and Drug	
		Administration (FDA) approved pharmacotherapy for	
		cessation to nonpregnant adults who use tobacco.	
Latent Tuberculosis	Adults	USPSTF Rating (Sept. 2016): B	
Infection: Screening		The USPSTF recommends screening for latent tuberculosis	
		infection (LTBI) in populations at increased risk. This	
		recommendation applies to asymptomatic adults 18 years	
Medication Use to Reduce	Women	and older at increased risk for tuberculosis. USPSTF Rating (Sept. 2019): B	
Risk of Breast Cancer	Women	The USPSTF recommends that clinicians offer to prescribe	
Misk of Breast earlier		risk reducing medications, such as tamoxifen, raloxifene, or	
		aromatase inhibitors, to women who are at increased risk	
		for breast cancer and at low risk for adverse medication	
		effects.	
Newborn Screenings	Newborns	USPSTF Rating (March 2008): A	
(Hypothyroidism,		Hypothyroidism Screening: Screening for congenital	
Phenylketonuria Screening		hypothyroidism in newborns (0-90 days).	
and Sickle Cell Screening)		USPSTF Rating (March 2008): A	
		Phenylketonuria Screening: Screening for phenylketonuria	
		(PKU) in newborns (0-90 days).	
		USPSTF Rating (Sept. 2007): A	
		Sickle Cell Screening: Screening for sickle cell disease in	
		newborns (0-90 days).	
Ocular Prophylaxis for	Newborns	USPSTF Rating (Jan. 2019): A	
Gonococcal Ophthalmia		The USPSTF recommends prophylactic ocular topical	
Neonatorum		medication for all newborns to prevent gonococcal	
		ophthalmia neonatorum.	

PREVENTIVE CARE SERVICES		
(Newborns, Children, Adolescents and Adults)		
Service	Population	Summary
Osteoporosis Screening	Women	USPSTF Rating (June 2018): B The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.
		USPSTF Rating (June 2018): B The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.
Perinatal Depression – Preventive Interventions (Counseling)	Pregnant and Postpartum Women	USPSTF Rating (Feb. 2019): B The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions.
Preeclampsia Screening	Pregnant Women	USPSTF Rating (April 2017): B The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.
Prevention of Falls in Community-Dwelling Older Adults	Adults	USPSTF Rating (April 2018): B The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.
Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis	Adolescents and Adults	USPSTF Rating (Aug. 2023): A The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. Includes related benefits: • Kidney function testing (creatinine), • Serologic testing for hepatitis B and C virus, • Testing for other STIs, • Pregnancy testing when appropriate and • Ongoing follow-up and monitoring, including HIV testing every 3 months.
Primary Care Interventions To Prevent Tobacco Use In Children And Adolescents	Children and Adolescents	USPSTF Rating (April 2020): B The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents. Bright Futures recommends tobacco use assessments from age 11-21 years.
Primary Care Interventions	Pregnant and	USPSTF Rating (Oct. 2016): B The USPSTF recommends providing interventions during

Postpartum Women

to Promote Breastfeeding

The USPSTF recommends providing interventions during

pregnancy and after birth to support breastfeeding.

PREVENTIVE CARE SERVICES		
(Newborns, Children, Adolescents and Adults)		
Service	Population	Summary
Rh(D) Incompatibility Screening	Pregnant Women	USPSTF Rating (Feb. 2004): A The USPSTF recommends Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy related care.
		USPSTF Rating (Feb. 2004): B The USPSTF recommends repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks gestation, unless the biological father is known to be Rh (D)-negative.
Screening and Behavioral Counseling Interventions in Primary Care to Reduce Unhealthy Alcohol Use in Adults	Adults	USPSTF Rating (Nov. 2018): B The USPSTF recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.
Screening for Anxiety Disorders in Adults	Adults	USPSTF Rating (June 2023): B The USPSTF recommends screening for anxiety disorders in adults (64 years or younger), including pregnant and postpartum persons.
Screening for Depression and Suicide Risk in Adults	Adults	USPSTF Rating (June 2023): B The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.
Screening for Depression and Suicide Risk in Children and Adolescents	Adolescents	USPSTF Rating (Oct. 2022): B The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 -18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.
Screening for High Blood Pressure (Hypertension) in Adults	Adults	USPSTF Rating (April 2021): A The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement. The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.
Screening for Intimate Partner Violence	Women	USPSTF Rating (Oct. 2018): B The USPSTF recommends that clinicians screen for intimate partner violence in women of reproductive age and provide or refer women who screen positive to ongoing support services.
Screening for Lung Cancer with Low-Dose Computed Tomography	Adults	USPSTF Rating (March 2021): B The USPSTF recommends annual screening for lung cancer with low dose computed tomography (LDCT) in adults aged

PREVENTIVE CARE SERVICES			
(New	(Newborns, Children, Adolescents and Adults)		
Service	Population	Summary	
		50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.	
Screening for Pre-Diabetes and Type 2 Diabetes	Adults	USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who are overweight or obese. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.	
Screening for Visual Impairment in Children	Children	USPSTF Rating (Sept. 2017): B The USPSTF recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors.	
Syphilis Screening	Adolescents and Adults	USPSTF Rating (Sept. 2022): A The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection (asymptomatic, nonpregnant adults and adolescents who are at increased risk for syphilis infection). USPSTF Rating (Sept. 2018): A The USPSTF recommends early screening for syphilis	
Unhealthy Drug Use Screening (Adults)	Adults	infection in all pregnant women. USPSTF Rating (June 2020): B The USPSTF recommends screening by asking questions about unhealthy drug use in adults aged 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)	
Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions	Adults	USPSTF Rating (Sept. 2018): B The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive multicomponent behavioral interventions.	
HRSA-Supported Women's Preventive Services Guidelines			
Breast Cancer Screening	Women	Recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. Note: Women at increased risk should also undergo periodic mammography	

PREVENTIVE CARE SERVICES			
(Newborns, Children, Adolescents and Adults)			
Service	Population	Summary	
		screening; however, recommendations for additional services are beyond the scope of this recommendation.	
Breastfeeding Services and Supplies	Women	WPSI recommends comprehensive lactation support services (including consultation; counseling; education by clinicians and peer support services; and breastfeeding equipment and supplies) during the antenatal, perinatal, and postpartum periods to optimize the successful initiation and maintenance of breastfeeding.	
		Breastfeeding equipment and supplies include, but are not limited to, double electric breast pumps (including pump parts and maintenance) and breast milk storage supplies. Access to double electric pumps should be a priority to optimize breastfeeding and should not be predicated on prior failure of a manual pump. Breastfeeding equipment may also include equipment and supplies as clinically indicated to support dyads with breastfeeding difficulties and those who need additional services.	
Contraception	Women	WPSI recommends that adolescent and adult women have access to the full range of contraceptives and contraceptive care to prevent unintended pregnancies and improve birth outcomes. Contraceptive care includes screening, education, counseling, and provision of contraceptives. Contraceptive care also includes follow-up care (e.g., management, evaluation and changes, including the removal, continuation, and discontinuation of contraceptives).	
		WPSI recommends that the full range of U.S. Food and Drug Administration (FDA) approved, granted, or cleared contraceptives, effective family planning practices, and sterilization procedures be available as part of contraceptive care. The full range of contraceptives includes those currently listed in the FDA's Birth Control Guide: (1) sterilization surgery for women, (2) implantable rods, (3) copper intrauterine devices, (4) intrauterine devices with progestin (all durations and doses), (5) injectable contraceptives, (6) oral contraceptives (combined pill), (7) oral contraceptives (progestin only), (8) oral contraceptives (extended or continuous use), (9) the contraceptive patch, (10) vaginal contraceptive rings, (11) diaphragms, (12) contraceptive sponges, (13) cervical caps, (14) condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), as well as any additional contraceptives approved, granted, or cleared by the FDA.	

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults) **Service Population** Summary Also, instruction in fertility awareness-based methods, including the lactation amenorrhea method, should be provided to women desiring an alternative method. Counseling for Sexually Women WPSI recommends directed behavioral counseling by a Transmitted Infections (STIs) health care clinician or other appropriately trained individual for sexually active adolescent and adult women at an increased risk for STIs. WPSI recommends that clinicians review a woman's sexual history and risk factors to help identify those at an increased risk of STIs. Note: For adolescents and women not identified as high risk, counseling to reduce the risk of STIs should be considered, as determined by clinical judgment. Obesity Prevention in Midlife Women WPSI recommends counseling midlife women aged 40 to 60 years with normal or overweight body mass index (BMI) Women (18.5-29.9 km/m2) to maintain weight or limit weight gain to prevent obesity. Counseling may include individualized discussion of healthy eating and physical activity. Screening and Counseling for Women Recommends screening adolescents and women for Interpersonal and Domestic interpersonal and domestic violence, at least annually, and, Violence when needed, providing or referring for initial intervention services. Interpersonal and domestic violence includes physical violence, sexual violence, stalking and psychological aggression (including coercion), reproductive coercion, neglect, and the threat of violence, abuse, or both. Intervention services include, but are not limited to, counseling, education, harm reduction strategies, and referral to appropriate supportive services. Screening for Anxiety Women The Women's Preventive Services Initiative (WPSI) recommends screening for anxiety in adolescent and adult women, including those who are pregnant or postpartum. Optimal screening intervals are unknown and clinical judgement should be used to determine screening frequency. Given the high prevalence of anxiety disorders, lack of recognition in clinical practices, and multiple problems associated with untreated anxiety, clinicians should consider screening women who have not been recently screened. Screening for Cervical Cancer Women Recommends cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years recommends cervical cancer screening using cervical cytology (Pap test) every 3 years. Cotesting with cytology and human papillomavirus testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with cytology and human papillomavirus testing every 5 years or cytology alone every 3 years.

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults) **Service Population** Summary Screening for Diabetes After Women WPSI recommends screening for type 2 diabetes in women Pregnancy with a history of gestational diabetes mellitus (GDM) who are not currently pregnant and who have not previously been diagnosed with type 2 diabetes. Initial testing should ideally occur within the first year postpartum and can be conducted as early as 4–6 weeks postpartum. Women who were not screened in the first year postpartum or those with a negative initial postpartum screening test result should be screened at least every 3 years for a minimum of 10 years after pregnancy. For those with a positive screening test result in the early postpartum period, testing should be repeated at least 6 months postpartum to confirm the diagnosis of diabetes regardless of the type of initial test (e.g., fasting plasma glucose, hemoglobin A1c, oral glucose tolerance test). Repeat testing is also indicated for women screened with hemoglobin A1c in the first 6 months postpartum regardless of whether the test results are positive or negative because the hemoglobin A1c test is less accurate during the first 6 months postpartum. Screening for Diabetes in Women WPSI recommends screening pregnant women for gestational diabetes mellitus after 24 weeks of gestation Pregnancy (preferably between 24 and 28 weeks of gestation) to prevent adverse birth outcomes. WPSI recommends screening pregnant women with risk factors for type 2 diabetes or GDM before 24 weeks of gestation—ideally at the first prenatal visit. Screening for Human Women The Women's Preventive Services Initiative (WPSI) Immunodeficiency Virus recommends all adolescent and adult women, ages 15 and (HIV) Infection older, receive a screening test for human immunodeficiency virus (HIV) at least once during their lifetime. Earlier or additional screening should be based on risk and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. The WPSI recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in labor with an undocumented HIV status.

WPSI recommends screening women for urinary

incontinence annually. Screening should assess whether women experience urinary incontinence and whether it impacts their activities and quality of life. The Women's

Screening for Urinary

Incontinence

Women

PREVENTIVE CARE SERVICES		
(Newborns, Children, Adolescents and Adults)		
Service	Population	Summary
		Preventive Services Initiative recommends referring women for further evaluation and treatment if indicated.
Well-Woman Exams	Women	WPSI recommends that women receive at least one preventive care visit per year beginning in adolescence and continuing across the lifespan to ensure the provision of all recommended preventive services, including preconception and many services necessary for prenatal and interconception care, are obtained. The primary purpose of these visits should be the delivery and coordination of recommended preventive services as determined by age and risk factors. These services may be completed at a single visit or as part of a series of visits that take place over time to obtain all necessary services.
Bright Future	s: Recommendation	ns for Preventive Pediatric Health Care
Anemia Screening	Children	Anemia screening in children up until the age of 22.
Depression Screening	Children	Depression screening at each of the recommended visits between age 12-21 years. Note: Maternal depression screening for postpartum depression should be integrated into well-child visits at 1, 2, 4 and 6 months of age.
Dyslipidemia Screening (Risk Assessment/Screening Lab Work)	Children	Risk Assessment recommended at 24 months, 4 years, 6 years, 8 years, 12 years, 13 years, 14 years, 15 years, 16 years. Screening Lab Work - conduct if risk assessment is positive, or, at the following intervals: once between age 9-11 years; once between age 17-21 years.
Fluoride Application in Primary Care – Prevention of Dental Caries	Children	For those at high risk, consider application of fluoride varnish for caries prevention every 3 to 6 months, between ages 6 months to 5 years.
Formal Developmental/Autism Screening	Children	Screening up until the age of 3.
Hearing Tests	Children	Hearing Tests - recommended at ages: Newborn; between 3-5 days to 2 months; 4 years; 5 years, 6 years; 8 years; 10 years; once between age 11-14 years; once between age 15-17 years; once between age 18-21 years; also recommended for those that have a positive risk assessment. Risk Assessment - recommended at ages: 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 24 months, 30 months, 3 years, 7 years, and 9 years.
HIV Screening	Children	HIV Risk Assessment: Conduct risk assessment at age 11 years, 12 years, 13 years and 14 years.

PREVENTIVE CARE SERVICES			
(Newborns, Children, Adolescents and Adults)			
Service	Population	Summary	
		HIV Screening Lab Work: Conduct once between age 15-21 years. Also, it is recommended anytime between ages 11-14 years when a risk assessment is positive.	
Lead Screening	Children	Lead screening, from ages 6 months until the age of 7.	
Psychosocial/Behavioral Assessment	Children	Assessments recommended up until the age of 22.	
Screening for Visual Impairment in Children	Children	Visual acuity screening is recommended for age 4 and 5 years as well as in cooperative 3-year-old children. Instrument-based screening recommended for age 12 and 24 months, in addition to the well visits at 3-5 years of age.	
Sexually Transmitted Infections (STI)	Children	STI Risk Assessment: Conduct risk assessment at each of the recommended visits between 11 years – 21 years.	
		STI Lab Work: Conduct if risk assessment is positive.	
Tobacco, Alcohol or Drug Use Assessment	Children	Assessments recommended from age 11-21 years.	
Tuberculosis Testing	Children	Testing until the age of 22.	
ACIP Rec	commendations: Ro	utine Immunizations for Children	
Chickenpox (Varicella)	Children (Carantha of	Two doses of the chickenpox shot are recommended for children by doctors as the best way to protect against chickenpox (varicella). One dose at each of the following ages: • 1 st Dose: 12 – 15 months, and • 2 nd Dose: 4 – 6 years. Older children or adolescents should also get two doses of the chickenpox if they have never received a chickenpox shot or never had chickenpox. They should also get a second shot if they have had only one chickenpox shot.	
COVID-19 Vaccine	Children (6 months of age and older)	See link for full details: https://www.cdc.gov/covid/vaccines/stay-up-to-date.html	
Diphtheria, Tetanus and Pertussis (DTaP)	Children	Five doses of the DTaP shot and a Tdap booster shot are recommended for children and preteens by doctors as the best way to protect against diphtheria. Note: Protects against diphtheria, as well as tetanus and whooping cough (pertussis). Recommended cadence: 1st Dose: 2 months, 2nd Dose: 4 months, 3rd Dose: 6 months, 4th Dose: 15 – 18 months, 5th Dose: 4 – 6 years, and	

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults)

(New	borns, Children,	Adolescents and Adults)
Service	Population	Summary
		 6th Dose: 11 or 12 years (booster vaccine called Tdap).
Haemophilus Influenzae Type b (Hib)	Children	Three or four doses, depending on the brand of the vaccine, are recommended for children by doctors as the best way to protect against Hib disease.
		One dose at each of the following ages: • 1 st Dose: 2 months, • 2 nd Dose: 4 months, • 3 rd Dose: 6 months (for some brands), and
Hepatitis A	Children	• 4 th Dose: 12 – 15 months. Two doses of the hepatitis A vaccine are recommended for children by doctors as the best way to protect against hepatitis A.
		One dose at each of the following ages: • 1 st Dose: 12 – 23 months, and • 2 nd Dose: 6 months after last dose.
Hepatitis B	Children	Three doses of the hepatitis B shot are recommended for children by doctors as the best way to protect against hepatitis B. One dose at each of the following ages: • 1 st Dose: Shortly after birth,
		 2nd Dose: 1- 2 months, and 3rd Dose: 6 – 18 months.
Human Papillomavirus (HPV)	Children	HPV vaccination is recommended at ages 11 – 12 years (Note: the vaccination can be given starting at 9 years, for special situations) to protect against cancers caused by HPV infection.
		Recommendations: • 11 – 12 years: • Two doses of the HPV shot are needed, 6 – 12 months apart.
		 If the shots are given less than 5 months apart, a 3rd dose is needed. If started after 15th birthday: Three doses of the HPV shot should be given over 6 months.
Inactivated Poliovirus	Children	Four doses of the polio shot for children are recommended by doctors as the best way to protect against polio.
		One dose at each of the following ages: • 1 st Dose: 2 months, • 2 nd Dose: 4 months,

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults)

(146	wborns, criniciei	i, Adolescents and Adults)
Service	Population	Summary
		 3rd Dose: 6 – 18 months, and
		 4th Dose: 4 – 6 years.
Influenza (flu shot)	Children	A yearly flu vaccine is the best way to protect your child
		from flu and its potentially serious complications.
		Doctors recommend children get a flu vaccine every year in
		the fall, starting when he/she is 6 months old. Note: Some
		children (6 months through 8 years of age) may need 2 doses for best protection.
Measles	Children	Two doses of the MMR vaccine are recommended for
ivicasies	Ciliarcii	children by healthcare providers as the best way to protect
		against measles, mumps and rubella.
		6
		One dose at each of the following ages:
		 1st Dose: 12 – 15 months, and
		• 2 nd Dose: 4- 6 years.
Meningococcal	Children	Two doses of the meningococcal shot called MenACWY are
		recommended for preteens and teens by doctors as the best
		way to protect against meningococcal disease.
		One dose at each of the following ages:
		1st Dose: 11 – 12 years, and
		• 2 nd Dose: 16 years.
Mumps	Children	Two doses of the MMR shot are recommended for children
		by doctors as the best way to protect against measles,
		mumps and rubella.
		One dose at each of the following ages:
		• 1 st Dose: 12 – 15 months, and
		• 2 nd Dose: 4 – 6 years.
Pneumococcal	Children	Four doses of the pneumococcal shot called PCV13 are
		recommended for children by doctors as the best way to protect against disease.
		protect against disease.
		One dose at each of the following ages:
		• 1 st Dose: 2 months,
		• 2 nd Dose: 4 months,
		3 rd Dose: 6 months, and
		• 4 th Dose: 12 – 15 months.
Rubella	Children	Two doses of the MMR shot (measles, mumps and rubella)
		are recommended for children by doctors as the best way to
		protect against rubella.
		One dose at each of the following ages:
		1st Dose: 12 – 15 months, and
		• 2 nd Dose: 4 – 6 years.
	1	(17)

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults)				
Rotavirus	Children	Two or more doses of a rotavirus are recommended for children by doctors as the best way to protect against rotavirus.		
		Babies should get either of the two available rotavirus vaccines:		
		 RotaTeq® (RV5) is given in three doses at ages 2 months, 4 months and 6 months, or Rotarix® (RV1) is given in two doses at ages 2 months and 4 months. 		
		Note: Both brands of the rotavirus vaccines are given by mouth (drops), not by shot.		
Respiratory Syncytial Virus Infection (RSV)	Children	Infants 8 months or younger born during or entering their first RSV season are recommended to receive one dose of Nirsevimab (50mg dose for infants <5kg in weight and 100 mg dose for infants greater than or equal to 5 kg).		
		Children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of Nirsevimab (200mg). The monoclonal antibody can be administered in the hospital after the baby is born or in the outpatient setting.		
ACIP R	ecommendations: R	outine Immunizations for Adults		
Chickenpox (Varicella)	Adults	If you aren't immune to chickenpox (if you haven't had chickenpox in the past or been vaccinated against), you need to get 2 doses of the vaccine about 1 month apart.		
Chikungunya Vaccine	Adults	Recommended for adults travelling to a country or territory where there is a chikungunya outbreak and for laboratory workers with potential exposure to the virus.		
		The vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years: • Persons aged over 65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitoes, or expersons staying for a cumulative period of 6 months or more * Moderate exposure could include travelers who might		
		have at least 2 weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings.		

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults) **Population** Service Summary Pregnant persons should avoid the risk for chikungunya virus infection, if possible. In general, vaccination should be deferred until after delivery. However, when the risk of infection is high and exposure cannot be avoided, a health care provider should discuss with a pregnant person the potential risks of chikungunya virus infection and the potential benefits and risks of vaccination so that vaccination can be considered. If pregnant persons choose to be vaccinated, out of caution vaccination should generally be avoided during the 1st trimester (until 14 weeks gestation) and after the 36th week of gestation. IXCHIQ is licensed for use in adults aged 18 years and older. It is administered intramuscularly as a single 0.5mL dose. There are currently no recommendations for a booster dose. COVID-19 Vaccine Adults See link for full details: https://www.cdc.gov/covid/vaccines/stay-up-to-date.html Diphtheria Adults All adults who have never received one should get a shot of Tdap. This can be given at any time, regardless of when they last got Td. This should be followed by either a Td or Tdap shot every 10 years. Note: Vaccines used today against diphtheria and tetanus (i.e., DT and Td) sometimes also include protection against whooping cough or pertussis (i.e., DTaP and Tdap). Babies and children younger than 7 years old receive DTaP or DT, while older children and adults receive Tdap and Td. Flu (Influenza) Adults Recommended once a year. Haemophilus Influenzae Adults 1 or 3 doses, depending on indication. Type b (Hib) Hepatitis A Adults Recommended for people at increased risk for hepatitis A, people at increased risk for severe disease from hepatitis A, pregnant women at risk for hepatitis A or risk for severe outcome from hepatitis A infection and any person who requests vaccination. There are two types of hepatitis A vaccine. The first type, the single-dose hepatitis A vaccine, is given as two shots, 6 months apart, and both shots are needed for long-term protection against hepatitis A. The other type is a combination vaccine that protects people against both hepatitis A and hepatitis B. The combination vaccine can be

given to anyone 18 years of age and older and is given as

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults) Service **Population** Summary three shots over 6 months. All three shots are needed for long-term protection for both hepatitis A and hepatitis B. Recommended for adults aged 19 through 59 years and Hepatitis B Adults adults aged 60 years and older with risk factors for hepatitis B. Note: Adults who are 60 years or older without known risk factors for hepatitis B may also receive hepatitis B vaccine. Human Papillomavirus (HPV) Adults Teens and young adults who start the series later (see above, Immunizations - Children), at ages 15 through 26 years, need three doses of HPV vaccine. Vaccination is not recommended for everyone older than age 26 years. However, some adults aged 27 – 45 years and not already vaccinated may decide to get HPV vaccine after speaking with their doctor about their risk. Adults Measles Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine. **Adults** There are 3 types of meningococcal vaccines available in the Meningococcal **United States:** Meningococcal conjugate or MenACWY vaccines (Menveo® and MenQuadfi®), Serogroup B meningococcal or MenB vaccines (Bexsero®and Trumenba®), and Pentavalent meningococcal or MenABCWY vaccine (Penbraya[™]) The CDC recommends: Routine MenACWY vaccination for adults at increased risk for meningococcal disease. Routine MenB vaccination for people 10 years or older at increased risk for meningococcal disease. The MenABCWY vaccination for people 10 years or older who are getting MenACWY and BenB vaccines at the same visit. Mpox (Monkeypox) Adults ACIP recommends vaccination with 2-dose JYNNEOS vaccine series for persons aged 18 years and older who are at risk for mpox. Dose 2 will be administered 28 days after dose 1. Mumps Adults Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine. Whooping Cough (Pertussis) **Adults** Pregnant women should get Tdap during the early part of the 3rd trimester of every pregnancy. Also, all adults who have never received one should get a shot of Tdap. This can be given at any time, regardless of when they last got Td. This should be followed by either a Td

or Tdap shot every 10 years.

PREVENTIVE CARE SERVICES (Newborns, Children, Adolescents and Adults) Service **Population** Summary Note: Vaccines used today against diphtheria and tetanus (i.e., DT and Td) sometimes also include protection against whooping cough or pertussis (i.e., DTaP and Tdap). Babies and children younger than 7 years old receive DTaP or DT, while older children and adults receive Tdap and Td. Pneumococcal Adults There are two kinds of pneumococcal vaccines available in the United States: Pneumococcal conjugate vaccines (PCV13, PCV15, PCV20 and PCV21), and Pneumococcal polysaccharide vaccine (PPSV23). For those who have never received any pneumococcal conjugate vaccine, the CDC recommends PCV15 or PCV20 for adults 65 years or older and adults 19 through 64 years old with certain medical conditions or risk factors. If PCV15 is used, this should be followed by a dose of PPSV23. Rubella Adults Adults who do not have presumptive evidence of immunity should get at least one dose of MMR vaccine. **Respiratory Syncytial Virus** Adults ACIP recommends adults 60-74 years of age who are at Infection (RSV) increased risk of severe RSV disease receive a single dose of RSV vaccine. (Adults aged 60-74 who are not at increased risk of severe RSV disease are not recommended to receive this vaccine.) ACIP recommends adults 75 years of age and older receive a single dose of RSV vaccine. Maternal RSV vaccine is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants. Please note that RSV vaccination is recommended as a single lifetime dose only. Persons who have already received RSV vaccination are not recommended to receive another dose. Shingles Adults The CDC recommends that adults 50 years and older get two doses of the shingles vaccine called Shingrix (recombinant zoster vaccine) to prevent shingles and the complications from the disease. Adults 19 years and older who have weakened immune systems because of disease or therapy should also get two doses of Shingrix, as they have a higher risk of getting shingles and related complications. There is no maximum age for getting Shingrix. **Tetanus** Adults Pregnant women should get Tdap during the early part of

the 3rd trimester of every pregnancy.

PREVENTIVE CARE SERVICES				
(Newborns, Children, Adolescents and Adults)				
Service	Population	Summary		
		All adults who have never received one should get a shot of Tdap. This can be given at any time, regardless of when they last got Td. This should be followed by either a Td or Tdap shot every 10 years. Note: Vaccines used today against diphtheria and tetanus (i.e., DT and Td) sometimes also include protection against whooping cough or pertussis (i.e., DTaP and Tdap). Babies and children younger than 7 years old receive DTaP or DT, while older children and adults receive Tdap and Td.		

IMPORTANT INFORMATION:

This document is intended as a reference tool and is not a guarantee of coverage nor payment. Covered services are only available to eligible members, in accordance with the guidelines addressed in the Evidence of Coverage (EOC) or Major Medical Expense Policy (MMEP). Please keep in mind, this document includes federal requirements only — national preventive care coverage — state required benefits are not addressed. However, we do cover additional preventive care benefits when required by state law, see EOC or MMEP for further details.

Ambetter from Nebraska Total Care is underwritten by Nebraska Total Care, Inc., which is a Qualified Health Plan issuer in the Nebraska Health Insurance Marketplace. This is a solicitation for insurance. ©2024 Nebraska Total Care, Inc., Ambetter.NebraskaTotalCare.com. For information on your right to receive an Ambetter from Nebraska Total Care plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit AmbetterHealth.com and scroll to the bottom of the page.



English:

If you, or someone you are helping, have questions about Ambetter from Nebraska Total Care, and are not proficient in English, you have the right to get help and information in your language at no cost and in a timely manner. If you, or someone you are helping, have an auditory and/or visual condition that impedes communication, you have the right to receive auxiliary aids and services at no cost and in a timely manner. To receive translation or auxiliary services, please contact Member Services at 1-833-890-0329 (TTY 711).

Spanish:

Si usted, o alguien a quien está ayudando, tiene preguntas acerca de Ambetter from Nebraska Total Care y no domina el inglés, tiene derecho a obtener ayuda e información en su idioma sin costo alguno y de manera oportuna. Si usted, o alguien a quien está ayudando, tiene un impedimento auditivo o visual que le dificulta la comunicación, tiene derecho a recibir ayuda y servicios auxiliares sin costo alguno y de manera oportuna. Para recibir servicios auxiliares o de traducción, comuníquese con Servicios para Miembros al 1-833-890-0329 (TTY 711).

Vietnamese:

Nếu quý vị hoặc người mà quý vị đang giúp đỡ có câu hỏi về Ambetter from Nebraska Total Care và không thành thạo tiếng Anh, quý vị có quyền được trợ giúp và nhận thông tin bằng ngôn ngữ của mình miễn phí và kịp thời. Nếu quý vị hoặc người mà quý vị đang giúp đỡ mắc bệnh về thính giác và/hoặc thị giác gây cản trở giao tiếp, quý vị có quyền được nhận các hỗ trợ và dịch vụ phụ trợ miễn phí và kịp thời. Để nhận dịch vụ thông dịch hoặc dịch vụ phụ trợ, vui lòng liên hệ bộ phận Dịch Vụ Thành Viên theo số 1-833-890-0329 (TTY 711).

Chinese:

如果您,或是您正在協助的對象,有關於 Ambetter from Nebraska Total Care 方面的問題,且不精通英語,您有權利免費並及時以您的母語獲幫助和訊息。如果您,或您正在協助的對象有聽力和/或視力上的問題,阻礙了溝通,您有權利免費並及時獲得輔助支援與服務。若要取得翻譯或輔助服務,請聯絡會員服務部,電話是 1-833-890-0329 (TTY 711)。

Arabic:

إذا كان لديك أو لدى شخص تساعده أسئلة حول Ambetter from Nebraska Total Care، ولم تكن بارعًا باللغة الإنكليزية، فلديك الحق في الحصول على المساعدة والمعلومات بلغتك من دون أي تكلفة وفي الوقت المناسب. إذا كنت أنت أو أي شخص تساعده تعاني من حالة سمعية و/أو بصرية تعيق التواصل، فلديك الحق في تلقي مساعدات وخدمات إضافية من دون أي تكلفة وفي الوقت المناسب. لتلقي خدمات الترجمة أو خدمات إضافية، يرجى الاتصال بـ خدمات الأعضاء على (TTY 711) 0329-830-1.

Karen:

နး, မ့တမ့်၊ ပှးလၢနမးစၢးအီးတဂၤ, မ့ါ်အိဉ်ဒီးတါ်သံကွါ် ဘဉ်ဃး Ambetter from Nebraska Total Care, ဒီး မ့ါတသဲ့ဘဉ် အဲကလုံးကျိုဉ်ဂုးဂုံးအဃိ, နအိဉ်ဒီး တါ်ခွဲးတါယာ်လ၊ ကဟုံးနှါ့ တါ်မးစၢးဒီး တါဂုါ်တါ်ကျိုးလ၊ နကျိုဉ်တါ်ကတ်းခုနဲ လ၊တလာ်ဘဉ် ကျိုာ်စဲ့ဒီး လ၊တါ်ဆ၊ကတီါ် ဖုဉ်ကိာ်အပူးနှဉ်လီး. နး, မဲ့တမ့ါ ပုံးလ၊နမးစ၊းအီးတဂၤ, အိဉ်ဒီး တါ်ကီတါ်ခဲတါ်အိဉ်သးဘဉ်ဃး တါ်နဉ်ဟူတါ ဒီး /မဲ့တမ့်၊ တါ်ထံဉ် လ၊အတြီဃာ် တါ်ဆဲးကျ၊ဆဲးကျိုးအဃိ, နအိဉ်ဒီး တါ်ခွဲးတါ်ယာ်လ၊ နကဒိုးနှါ့ တါမးစ၊းဆီဉ်ထွဲဒီး တါ်တိစ၊းမးစ၊းတဖဉ် လ၊တလာ်ဘဉ် ကျိုာ်စဲ့ဒီး လ၊တါ်ဆ၊ကတီါ် ဖုဉ်ကိာ်အပူးနှဉ်လီး. ဒ်သိနကဒိုးနှါ့ တါ်ကတိးကျိုးထံ မဲ့တမ့်၊ တါမးစ၊းဆီဉ်ထွဲ အတါဖုံးတါမ်းတဖဉ်အဂ်ီ၊ ဝံသးစူး ဆဲးကျိုး ဆူ တါမ်းစ၊း ကရူါဖိဖဲ 1-833-890-0329 (TTY 711) နှဉ်တကု).

French:

Si vous-même ou une personne que vous aidez avez des questions à propos d'Ambetter from Nebraska Total Care et que vous ne maîtrisez pas l'anglais, vous pouvez bénéficier gratuitement et en temps utile d'aide et d'informations dans votre langue. Si vous-même ou une personne que vous aidez souffrez d'un trouble auditif ou visuel qui entrave la communication, vous pouvez bénéficier gratuitement et en temps utile d'aides et de services auxiliaires. Pour profiter de services de traduction ou de services auxiliaires, veuillez contacter Services aux membres au 1-833-890-0329 (TTY 711).

Cushite:

Isin, ykn namni biraa isin gargaartan, Ambetter from Nebraska Total Care gaaffii qabdu yoo ta'ee fiAfaan Ingiliffaa hin beektanu taanan, yeroodhaan afaan barbaaddaniin kaffaltii tokko malee odeeffannoo barbaaddan argachuudhaaf mirga qabdu. Isin, ykn namni isin gargaartan, rakkoo dhageettii fi/ykn agartii kan haasaa keessan irratti dhiibbaa qabu qabdu taanan, gargaarsa dhageettii argachuu fi tajaajiloota kaffaltii malee argachuudhaaf mirga qabdu. Tajaajiloota hiikkaa afaanii fi dhageettii argachuudhaaf, maaloo Tajaajiloota Maamilaa karaa 1-833-890-0329 (TTY 711) qunnamaa.

German:

Falls Sie oder jemand, dem Sie helfen, Fragen zu Ambetter from Nebraska Total Care hat und nicht Englisch spricht, haben Sie das Recht, kostenlos und zeitnah Hilfe und Informationen in Ihrer Sprache zu erhalten. Falls Sie oder jemand, dem Sie helfen, eine Hör- und/oder Sehbeeinträchtigung hat, die die Kommunikation beeinflusst, haben Sie das Recht, kostenlos und zeitnah zusätzliche Hilfe und Dienstleistungen zu erhalten. Um eine Übersetzung oder zusätzliche Dienstleistungen zu erhalten, wenden Sie sich an den Kundendienst unter 1-833-890-0329 (TTY 711).

Korean:

귀하 또는 귀하의 도움을 받는 분이 Ambetter from Nebraska Total Care에 대한 질문이 있는 경우영어에 능숙하지 않으시면 해당 언어로 시의적절하게 무료 지원과 정보를 받을 권리가 있습니다. 귀하 또는 귀하의 도움을 받는 분이 청각 및/또는 시각적으로 의사소통에 장애가 있는 경우 시의적절하게 무료 보조 도구 및 서비스를 받을 권리가 있습니다. 번역 또는 보조 서비스를 받으시려면 1-833-890-0329 (TTY 711)번으로 가입자 서비스부에 연락해주십시오.

Nepali:

यदि तपाईं स्वयं वा तपाईंले मद्दत गरिरहनुभएको कोही व्यक्तिसँग Ambetter from Nebraska Total Care सँग सम्बन्धित प्रश्नहरू छन् र तपाईं दुवै अंग्रेजीमा निपुण हुनुहुन्न भने तपाईंसँग निःशुल्क रूपमा र समयमै आफ्नो भाषामा मद्दत र जानकारी प्राप्त गर्ने अधिकार छ। यदि तपाईं वा तपाईंले मद्दत गरिरहनुभएको व्यक्तिसँग सञ्चारमा बाधा पुऱ्याउने श्रवण र/वा दृश्यसम्बन्धी समस्या छ भने तपाईंसँग निःशुल्क रूपमा र समयमै सहायक उपकरण र सेवाहरू प्राप्त गर्ने अधिकार छ। अनुवाद वा सहायक सेवाहरू प्राप्त गर्ने कृपया 1-833-890-0329 (TTY 711) मा सदस्य सेवाहरू लाई सम्पर्क गर्नुहोस्।

Russian:

Если у вас или у лица, которому вы помогаете, возникли какие-либо вопросы о программе страхования Ambetter from Nebraska Total Care, при этом вы недостаточно хорошо владеете английским языком, вы имеете право на бесплатную и своевременную помощь и информацию на своем родном языке. Если у вас или у лица, которому вы помогаете, наблюдается какое-либо нарушение слуха и/или зрения, которое препятствует коммуникации, вы имеете право на бесплатные и своевременные вспомогательные услуги и помощь. Для получения услуг перевода или вспомогательных услуг обратитесь в отдел обслуживания участников программы страхования по номеру 1-833-890-0329 (ТТҮ 711).

Laotian:

ຖ້າຫາກທ່ານ ຫຼື ຜູ້ໃດຜູ້ໜຶ່ງທີ່ທ່ານກຳລັງໃຫ້ການຊ່ວຍເຫຼືອ, ມີຄຳຖາມກ່ຽວກັບ Ambetter from Nebraska Total Care, ແລະ ບໍ່ຊ່ຽວຊານພາສາອັງກິດ, ທ່ານມີສິດໄດ້ຮັບການຊ່ວຍເຫຼືອ ແລະ ຂໍ້ມູນທີ່ເປັນພາສາຂອງທ່ານໂດຍບໍ່ມີຄ່າໃຊ້ຈ່າຍ ແລະ ທັນເວລາ. ຖ້າຫາກທ່ານ ຫຼື ຜູ້ໃດຜູ້ໜຶ່ງທີ່ທ່ານກຳລັງໃຫ້ການຊ່ວຍເຫຼືອ, ມີສະພາບທາງການໄດ້ຍິນ ແລະ/ຫຼື ການເບິ່ງເຫັນທີ່ຂັດຂວາງການສື່ສານ, ທ່ານມີສິດໄດ້ຮັບການຊ່ວຍເຫຼືອ ແລະ ການບໍລິການເສີມໂດຍບໍ່ມີຄ່າໃຊ້ຈ່າຍ ແລະ ທັນເວລາ. ເພື່ອໃຫ້ໄດ້ຮັບການບໍລິການແປພາສາ ຫຼື ບໍລິການເສີມ, ກະລຸນາຕິດຕໍ່ຫາ Member Services (ການບໍລິການສະມາຊິກ) ໄດ້ທີ່ 1-833-890-0329 (TTY 711).

Kurdish:

Eger pirsên we, yan jî kesekî ku hûn arîkariya wî dikin, li ser Ambetter from Nebraska Total Care hebin, û ser Îngilîsî şareza nebin, heqê we heye ku bi zimanê xwe bi awayê belaş û di wextê guncan de arîkarî û zanyariyan wergirin. Eger rewşa we, yan jî ya kesekî ku hûn alîkariya wî dikin, ya bihîstin an dîtinê ya ku pêwendiyê asteng dike hebe, , heqê we heye ku arîkarî û xizmetên arîkar bi awayê belaş û di wextê guncan de wergirin. Ji bo wergirtina wergerê yan xizmetên arîkar, ji kerema xwe bi Xizmetên Endaman bi hejmara 1-833-890-0329 (TTY 711) pêwendiyê çêbikin.

Persian:

اگر شما یا فردی که دارید به او کمک می کنید، سؤالی درباره Ambetter from Nebraska Total Care دارید، و انگلیسی نمی دانید، حق دارید کمک و اطلاعات را به زبان خودتان به رایگان و به موقع دریافت کنید. اگر شما یا فردی که دارید به او کمک می کنید مشکلات شنوایی یا بینایی دارد که برقراری ارتباط را سخت می کند، حق دارید کمکها و خدمات امدادی را به زبان خودتان به رایگان و به موقع دریافت کنید. برای دریافت کمکها و خدمات امدادی لطفاً با خدمات اعضا به شماره (TTY 711) 0329-893-833-1 تماس بگیرید.

Japanese:

ご自身やあなたが介護している他の人が、Ambetter from Nebraska Total Careについてご質問をお持ちの場合、英語に自信がなくても無料かつタイムリーにご希望の言語でヘルプや情報を得ることができます。ご自身や、あなたが介護している他の人の聴覚や視覚の状態のためやり取りが難しい場合でも、無料かつタイムリーに補助サービスを受けることができます。翻訳や補助サービスを受けるには、1-833-890-0329 (TTY 711)のメンバーサービスにご連絡ください。

AMB24-NE-C-00014

Ambetter from Nebraska Total Care is underwritten by Nebraska Total Care, Inc. which is a Qualified Health Plan issuer in the Nebraska Health Insurance Marketplace. This is a solicitation for insurance. ©2024 Nebraska Total Care, Inc., Ambetter.NebraskaTotalCare.com. If you, or someone you're helping, have questions about Ambetter from Nebraska Total Care, and are not proficient in English, you have the right to get help and information in your language at no cost and in a timely manner. If you, or someone you're helping, have an auditory and/or visual condition that impedes communication, you have the right to receive auxiliary aids and services at no cost and in a timely manner. To receive translation or auxiliary services, please contact Member Services at 1-833-890-0329 (TTY 711). For more information on your right to receive an Ambetter from Nebraska Total Care plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit AmbetterHealth.com and scroll to the bottom of the page.